As of 2025-07-09, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (4,462.93) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -52605.1%.
The range of the Relative Valuation is (3,599.75) - (5,011.08) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.6x - 23.9x | 19.8x |
| Forward P/E multiples | 17.1x - 28.4x | 22.8x |
| Fair Price | (3,599.75) - (5,011.08) | (4,462.93) |
| Upside | -42450.0% - -59053.9% | -52605.1% |
| Date | P/E |